<?xml version='1.0' encoding='utf-8'?>
<document id="16702113"><sentence text="Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns." /><sentence text="CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity" /><sentence text=" To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates"><entity charOffset="116-125" id="DDI-PubMed.16702113.s3.e0" text="midazolam" /><entity charOffset="127-137" id="DDI-PubMed.16702113.s3.e1" text="nifedipine" /><entity charOffset="139-151" id="DDI-PubMed.16702113.s3.e2" text="testosterone" /><entity charOffset="156-167" id="DDI-PubMed.16702113.s3.e3" text="terfenadine" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e0" e2="DDI-PubMed.16702113.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e0" e2="DDI-PubMed.16702113.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e0" e2="DDI-PubMed.16702113.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e0" e2="DDI-PubMed.16702113.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e1" e2="DDI-PubMed.16702113.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e1" e2="DDI-PubMed.16702113.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e1" e2="DDI-PubMed.16702113.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e2" e2="DDI-PubMed.16702113.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16702113.s3.e2" e2="DDI-PubMed.16702113.s3.e3" /></sentence><sentence text=" Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively"><entity charOffset="77-89" id="DDI-PubMed.16702113.s4.e0" text="testosterone" /><entity charOffset="114-125" id="DDI-PubMed.16702113.s4.e1" text="terfenadine" /><entity charOffset="148-153" id="DDI-PubMed.16702113.s4.e2" text="TFDOH" /><pair ddi="false" e1="DDI-PubMed.16702113.s4.e0" e2="DDI-PubMed.16702113.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16702113.s4.e0" e2="DDI-PubMed.16702113.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16702113.s4.e0" e2="DDI-PubMed.16702113.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16702113.s4.e1" e2="DDI-PubMed.16702113.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16702113.s4.e1" e2="DDI-PubMed.16702113.s4.e2" /></sentence><sentence text=" In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4" /><sentence text=" An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alphaNF) and CYP3A substrates were different for the two CYP3A enzymes"><entity charOffset="64-84" id="DDI-PubMed.16702113.s6.e0" text="alpha-naphthoflavone" /></sentence><sentence text=" alphaNF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4"><entity charOffset="20-30" id="DDI-PubMed.16702113.s7.e0" text="nifedipine" /></sentence><sentence text=" alphaNF at less than 32 microM inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4"><entity charOffset="42-51" id="DDI-PubMed.16702113.s8.e0" text="TFDOH" /></sentence><sentence text=" These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions" /><sentence text="" /></document>